A federal judge approves Teva's $35M settlement with health funds over delayed QVAR generic inhalers, requiring Teva to delist six Orange Book patents.
A Massachusetts federal judge on Wednesday approved a $35 million settlement between Teva Pharmaceuticals and a handful of healthcare funds over allegations the company delayed …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sandoz strikes US settlements to resolve generic drug price dispute
Swiss pharma firm Sandoz to pay $450 million in US antitrust suit
Sandoz floats nearly $500M to resolve bulk of lingering US antitrust claims
Drugmakers don’t have ‘duty to innovate’, California court rules, backing Gilead in HIV drug litigation
Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states
